Keep the names distinct
Retatrutide and cagrilintide are different investigational compounds, not alternative names for semaglutide or tirzepatide. A study, sponsor update or online product label may discuss one alone or as part of a combination. The exact intervention matters before drawing conclusions about either evidence or cost.
Sources: FDA — concerns with unapproved GLP-1 drugs, Lilly — TRIUMPH-1 trial
Start with the current FDA statement
FDA’s unapproved-GLP-1 page states that retatrutide and cagrilintide are not components of an FDA-approved drug and cannot be used in compounding under federal law. This is the agency’s stated position in the checked source, not a claim that a research vendor’s label changes the rules. A research-use label does not turn an online vial into an approved patient treatment.
Sources: FDA — concerns with unapproved GLP-1 drugs, Lilly — TRIUMPH-1 trial
A sponsor trial has a defined protocol
Lilly’s TRIUMPH-1 page identifies a retatrutide clinical study with a specific study population and protocol. Participation is a research process governed by that study; it is not a retail subscription or assurance of enrollment. Study outcomes also cannot authenticate an unrelated seller’s product, establish its contents or predict an individual response.
Sources: FDA — concerns with unapproved GLP-1 drugs, Lilly — TRIUMPH-1 trial
Why no consumer price ranking appears here
We do not combine research-chemical prices with prescribed medicine offers as if they were equivalent purchasing options. For these compounds, product status comes before price arithmetic. Readers comparing established clinical treatment costs can use the separately labeled semaglutide and tirzepatide boards, keeping approved products, compounded preparations and care-only fees distinct.
Sources: FDA — concerns with unapproved GLP-1 drugs, Lilly — TRIUMPH-1 trial
Keep reading.
Follow the evidence
Sources & price notes
Each source retains its own check date. Provider pages document advertised terms; they do not independently establish clinical outcomes.
- FDA — concerns with unapproved GLP-1 drugs ↗
Safety, dosing errors, salt forms and misleading online marketing. Regulatory page rechecked October 9, 2026; retain distinctions between approval, risk information and compounding nominations.
Checked October 9, 2026
- Lilly — TRIUMPH-1 trial ↗
Sponsor trial information identifies investigational retatrutide and a defined study population. A trial is not a retail product approval.
Checked October 9, 2026